Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. (Q51862683)

From Wikidata

Jump to navigation Jump to search

scientific article published in September 2008

Language	Label	Description	Also known as
English	Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.	scientific article published in September 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

0 references

cervix uterine cancer

1 reference

based on heuristic

inferred from title

5

object named as

Chien-Jen Chen

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Francesc Xavier Bosch José

3

object named as

F Xavier Bosch

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

author name string

Eugenio Suárez

1

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Jennifer S Smith

2

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Pekka Nieminen

4

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Saku Torvinen

6

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Nadia Demarteau

7

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Baudouin Standaert

8

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

language of work or name

0 references

publication date

1 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

26 Suppl 5

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

F29-45

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

Evolution of the health economics of cervical cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Model for assessing human papillomavirus vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Cost-effectiveness of a potential vaccine for human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Evaluating human papillomavirus vaccination programs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Hepatitis B immunization in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Need for differential discounting of costs and health effects in cost effectiveness analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Discounting in decision making: the consistency argument revisited empirically.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Economic rate of discount and estimating cost benefit of viral immunisation programmes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Discounting health effects in pharmacoeconomic evaluations: current controversies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Chapter 14: HPV vaccine introduction in industrialized countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus infection and genital warts: update on epidemiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Development and duration of human papillomavirus lesions, after initial infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Genital warts and their treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus: burden of illness and treatment cost considerations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Meta-analysis of Pap test accuracy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Cervical cancer: the Chilean perspective. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

[Epidemiology of HPV infection]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Natural history of cervical squamous intraepithelial lesions: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Natural history of dysplasia of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Natural history of cervicovaginal papillomavirus infection in young women.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

The genotypes and prognostic significance of human papillomaviruses in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Human papillomavirus genotype in cervical cancer: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.05.069

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.05.069

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 April 2018

http://europepmc.org/abstract/MED/18992380

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51862683&oldid=2043810777"